In yet another trouble for the pharmaceuticals major Ranbaxy Laboratories, a public interest Litigation (PIL) appeal has been filed in the Supreme Court against the company’s directors for allegedly manufacturing and selling adulterated drugs. Manohar Lal Sharma, the petitioner, has also sought sealing of the company’s manufacturing facilities at Paonta Sahib and Devas in Madhya Pradesh, besides mentioning the Central Bureau of Investigation (CBI) as one of the respondents in the case.
The PIL comes in the wake of the Indian pharma major being fined $500 million by the U.S. Food and Drug Administration (USFDA) for making and selling 'adulterated' drugs
Further, Sharma has also sought action against the drug regulator, Central Drug Standards Control Organization for permitting Ranbaxy to sell drugs in India, especially after the findings of the US FDA against the company. The petition which mentioned before a bench of judges Gyan Sudha Misra and Madan B Lokur would be heard next week.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: